Dr. Oliver H. F. Scholle

  • September 2020 PhD degree at the University of Bremen (Title: "Utilization of pharmacological and non-pharmacological treatment in children and adolescents with attention deficit/hyperactivity disorder: Analyses based on primary and secondary data")
  • since October 2014 Research Fellow at Leibniz Institute for Prevention Research and Epidemiology – BIPS in the department Clinical Epidemiology
  • March 2012 – October 2014 Master of Science in Consumer Health Care (Charité, Berlin).
    Master thesis at BIPS in the department Clinical Epidemiology, Unit Drug Safety: "Comedication with antipsychotics and antidepressants of ADHD children and adolescents: a population-based cohort study"
  • July 2012 – September 2014 Nationwide locum pharmacist
  • April 2010 – April 2012 Employee in a pharmacy
  • October 2010 – March 2019 Employment in and initiation of the internet platform pharma4u
  • December 2008 – June 2009 Diploma thesis at the Institute of Clinical and Experimental Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel: "Development of a LC/MS method for analysing Piritramide in plasma"
  • October 2003 – November 2008 Study of Pharmacy at the Universities of Marburg and Kiel

  • Health Services Research
  • Drug Utilization Research
  • Pharmacoepidemiology
  • Neuropsychiatric diseases (particularly ADHD)

ORCID logo
ORCiD: 0000-0002-2633-6587

Selected BIPS-Publications

  • Articles with peer review

  • Bachmann CJ, Zillmer S, Schink T, Scholle OHF, Fegert JM. Prevalence, psychiatric comorbidity and treatment of multiple personality disorder in Germany: An analysis based on nationwide claims data, 2012-2021. European Journal of Psychotraumatology. 2026;17(1):2640814.
    https://doi.org/10.1080/20008066.2026.2640814
  • Degen M, Haug U, Scholle OHF, Awuku-Larbi Y, Carlsson S, Ebert N, Harth V, Hauri AM, Heier M, Herrmann A, Leitzmann M, Linseisen J, Meinke-Franze C, Obi N, Pendt P, Reinhold T, Thorand B, Brenner H, Schöttker B. Factors associated with potentially inappropriate medication use, medication underuse, and overuse in older adults in the German National Cohort. Journal of Internal Medicine. 2026;299(6):754-775.
    https://doi.org/10.1111/joim.70097
  • Scholle OHF, Jobski K, Viebrock J, Haug U. Prescribing of opioid analgesics in Germany: Opposite trends when different quantification measures are used. Clinical Epidemiology. 2026;18:280510.
    https://doi.org/10.2147/clep.s580510
  • Scholle OHF, Riedel O, Qubad M, Dörks M, Kollhorst B, Bittner R, Bachmann CJ. Clozapine prescribing in Germany: Temporal trends and regional variations, 2012-2022. Schizophrenia. 2026;12:44.
    https://doi.org/10.1038/s41537-026-00763-w
  • Chan AYL, Bahmanyar S, Beyene K, Bushnell G, Carleton B, Chan AHY, Cook S, Crystal S, Furu K, Gadzhanova S, García Poza P, Gini R, Giometto S, Harrison J, Haug U, Hsu C, Hjördisar Jónsdóttir HL, Kai J, Karlstad Ø, Kim JH, Kubota K, Chia-Cheng Lai E, Lee H, Lau WCY, Li KH, Lucenteforte E, Géric M, Neumann A, Pate V, Pottegård A, Qureshi N, Rasmussen L, Reutfors J, Roughead EE, Saastamoinen L, Sato T, Scholle OHF, Schuiling-Veninga CCM, Shen C-Y, Shin J-Y, Stürmer T, Taxis K, Tuccori M, Weng S, Wong KH.W, Zoega H, Man KKC, Wong ICK. International trends in opioid prescribing by age and sex from 2001 to 2019: An observational study using population-based databases from 18 countries and one special administrative region. CNS Drugs. 2025;39(11):1173-1185.
    https://doi.org/10.1007/s40263-025-01215-2
  • Riedel O, Bachmann C, Bittner R, Dörks M, Kollhorst B, Qubad M, Scholle OHF. Prevalence and incidence of treated schizophrenia: Temporal and regional trends in Germany. Schizophrenia. 2025;11:131.
    https://doi.org/10.1038/s41537-025-00689-9
  • Bachmann CJ, Scholle OHF, Bliddal M, DosReis S, Odsbu I, Skurtveit S, Wesselhoeft R, Vivirito A Zhang, Chengchen, Scott S. Recognition and management of children and adolescents with conduct disorder: A real-world data study from four western countries. Child and Adolescent Psychiatry and Mental Health. 2024;18:18.
    https://doi.org/10.1186/s13034-024-00710-6
  • Scholle OHF, Rasmussen L, Reilev M, Viebrock J, Haug U. Comparative analysis of outpatient antibiotic prescribing in early life: A population-based study across birth cohorts in Denmark and Germany. Infectious Diseases and Therapy. 2024;13(2):299-312.
    https://doi.org/10.1007/s40121-024-00916-3
  • Schüz B, Scholle OHF, Haug U, Tillmann R, Jones C. Drivers of district-level differences in outpatient antibiotic prescribing in Germany: A qualitative study with prescribers. BMC Health Services Research. 2024;24:589.
    https://doi.org/10.1186/s12913-024-11059-z
  • Wharton GT, Becker C, Bennett D, Burcu M, Bushnell G, Ferrajolo C, Kaplan S, McMahon AW, Movva N, Raman SR, Scholle OHF, Suh M, Sun JW, Horton DB. Overview of global real-world data sources for pediatric pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety. 2024;33(1):e5695.
    https://doi.org/10.1002/pds.5695
    https://repository.publisso.de/resource/frl%3A6525229
  • Dörks M, Bachmann CJ, Below M, Hoffmann F, Paschke LM, Scholle OHF. Trends in antipsychotic use among children and adolescents in Germany: A study using 2011-2020 nationwide outpatient claims data. Frontiers in Psychiatry. 2023;14:1264047.
    https://doi.org/10.3389/fpsyt.2023.1264047
  • Scholle OHF, Asendorf M, Buck C, Grill S, Jones C, Kollhorst B, Riedel O, Schüz B, Haug U. Regional variations in outpatient antibiotic prescribing in Germany: A small area analysis based on claims data. Antibiotics. 2022;11(7):836.
    https://doi.org/10.3390/antibiotics11070836
  • Riedel O, Klau S, Langner I, Bachmann CJ, Scholle OHF. Prevalence of multimodal treatment in children and adolescents with ADHD in Germany: A nationwide study based on health insurance data. Child and Adolescent Psychiatry and Mental Health. 2021;15:76.
    https://doi.org/10.1186/s13034-021-00431-0
  • Scholle OHF, Kollhorst B, Riedel O, Bachmann CJ. First-time users of ADHD medication among children and adolescents in Germany: An evaluation of adherence to prescribing guidelines based on claims data. Frontiers in Psychiatry. 2021;12:653093.
    https://doi.org/10.3389/fpsyt.2021.653093
  • Scholle OHF, Neubert A, Riedel O, Toni I, Haug U. Repeated use of prescription drugs in pediatrics: Comprehensive overview based on German claims data. Frontiers in Pharmacology. 2021;12:706682.
    https://doi.org/10.3389/fphar.2021.706682
  • Scholle OHF, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Kölch M. Predictors for receiving medication and/or psychotherapy in children newly diagnosed with ADHD: A longitudinal population-based cohort study. Journal of Attention Disorders. 2020;24(2):255-264.
    https://doi.org/10.1177/1087054718816172
    https://repository.publisso.de/resource/frl%3A6417559
  • Scholle OHF, Kollhorst B, Haug U. Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. Journal of Internal Medicine. 2020;287(2):171-179.
    https://doi.org/10.1111/joim.12990
  • Vassilev ZP, Soriano-Gabarró M, Kaye JA, Saltus CW, Riedel O, Scholle OHF, Mehtälä J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: Results from observational studies in three countries. Future Oncology. 2020;16(25):1889-1901.
    https://doi.org/10.2217/fon-2020-0315
  • Langner I, Haug U, Scholle OHF, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. Journal of Clinical Psychopharmacology. 2019;39(1):39-45.
    https://doi.org/10.1097/JCP.0000000000000980
    https://repository.publisso.de/resource/frl%3A6423245
  • Scholle OHF, Jilani H, Riedel O, Banaschewski T, Hadjigeorgiou C, Hunsberger M, Iguacel I, Molnár D, Pala V, Russo P, Veidebaum T, Zaqout M, Pohlabeln H, on behalf of the I.Family consortium. Use of nutritional supplements in youth with medicated and unmedicated attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2019;29(1):58-65.
    https://doi.org/10.1089/cap.2018.0060
    https://repository.publisso.de/resource/frl%3A6423292
  • Castellsagué J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle OHF, Calingaert B, Bui C, Arana A, Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthan S. Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety. 2018;27(9):953-961.
    https://doi.org/10.1002/pds.4584
  • Scholle OHF, Banaschewski T, Enders D, Garbe E, Riedel O. Use and characteristics of antipsychotic/methylphenidate combination therapy in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2018;28(6):415-422.
    https://doi.org/10.1089/cap.2018.0024
    https://repository.publisso.de/resource/frl%3A6417060
  • Castellsagué J, Perez-Gutthan S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Giner-Soriano M, Roso-Llorach A, Kieler H, Linder M, Citarella A, Scholle OHF, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety. 2017;26(6):615-624.
    https://doi.org/10.1002/pds.4167

  • Articles without peer review

  • Scholle OHF, Lappe V, Meyer I, Viebrock J, Schwarz S, Haug U. Anwendung von kombinierten hormonalen Kontrazeptiva in Deutschland. Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI. 2026;1:11-17.
    https://www.bfarm.de/DE/Aktuelles/Publikationen/Bulletin/Ausgaben/_node.html
  • Schäfer W, Scholle OHF, Viebrock J, Haug U. Verordnung von testosteronhaltigen Arzneimitteln in Deutschland. Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI. 2025;3:4-8.
    https://www.bfarm.de/DE/Aktuelles/Publikationen/Bulletin/Ausgaben/_node.html
  • Scholle OHF, Viebrock J, Haug U. Anwendung von opioidhaltigen Analgetika in Deutschland. Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI. 2025;1:37-41.
    https://www.bfarm.de/DE/Aktuelles/Publikationen/Bulletin/Ausgaben/_node.html

  • PhD-Theses

  • Scholle OHF. Nutzung medikamentöser und nicht-medikamentöser Therapien bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung: Primär- und Sekundärdaten-basierte Analysen. Bremen: Universität Bremen; 2020.
    https://doi.org/10.26092/elib/246

  • Presentations at scientific meetings/conferences

  • Enners S, Schlotmann A, Schüssel K, Brückner G, Jobski K, Langner I, Thiede M, Scholle OHF. District-level differences in opioid prescribing in Germany (2023): Results from a population-based study. Jena. 2025.
  • Scholle OHF, Kollhorst B, Heinig M, Haug U. Real-world use of pembrolizumab in Germany: Patient characteristics and survival. Jena. 2025.
  • Bachmann CJ, Bittner R, Riedel O, Scholle OHF. Verschreibung von Clozapin bei Menschen mit Schizophrenie in Deutschland: Prävalenz, zeitliche Trends und regionale Unterschiede im Zeitraum 2010-2021. Berlin. 2024.
  • Scholle OHF, Jobski K, Viebrock J, Haug U. Wachsende regionale Unterschiede nach Urbanität und sozioökonomischer Benachteiligung in der Verschreibungsprävalenz von Opioid-Analgetika bei nicht-tumorbedingten Schmerzen: Ergebnisse basierend auf deutschen Krankenkassendaten von 2004 bis 2020. Bonn. 2024.
  • Buck C, Scholle OHF, Kollhorst B, Haug U. Area-level analysis of regional socio-economic factors on outpatient antibiotic prescribing including claims data from 16 million persons in Germany. Würzburg. 2023.
  • Scholle OHF, Jobski K, Viebrock J, Haug U. Verschreibung von Opioid-Analgetika in Deutschland: Gegensätzliche Trends bei Verwendung unterschiedlicher Maßzahlen zur Quantifizierung. Köln. 2023.
  • Scholle OHF, Jobski K, Viebrock J, Haug U. Prescribing of opioid analgesics in Germany: Opposite trends when different quantification measures are used. Halifax, Canada. 2023.
  • Schüz B, Jones C, Scholle OHF, Haug U. Regional variations in antibiotic prescribing in Germany: Understanding differences through an adapted theoretical domains framework. Bremen. 2023.
  • Scholle OHF, Rasmussen L, Reilev M, Viebrock J, Haug U. Outpatient antibiotic prescribing in early life: A population-based study comparing birth cohorts from Denmark and Germany. Münster. 2022.
  • Scholle OHF, Asendorf M, Buck C, Grill S, Riedel O, Haug U. Antibiotic prescribing in children aged 0-6 years in Germany: Assessing regional variations and potential explanations based on claims data. Online-Vortrag. 2021.
  • Scholle OHF, Asendorf M, Buck C, Grill S, Riedel O, Haug U. Antibiotic prescribing in children aged 0-6 years in Germany: Assessing regional variations and potential explanations based on claims data. online presentation. 2021.
  • Scholle OHF, Grill S, Haug U. Early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. Online-Vortrag. 2020.
  • Scholle OHF, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. Online-Vortrag. 2020.
  • Scholle OHF, Kollhorst B, Haug U. Diclofenac use and cardiovascular contraindications: Risk minimisation measures lacking effectiveness in Germany - A claims data analysis. Ulm. 2019.
  • Schröder C, Scholle OHF, Riedel O. Using administrative data to examine extent and risks of psychotropic drug use in children and adolescents. Possibilities and limitations. Munich. 2016.

  • Presentations at scientific meetings/conferences (invited)

  • Scholle OHF, Rasmussen L, Reilev M, Viebrock J, Haug U. Ambulante Verordnung von Antibiotika im frühen Leben: Eine bevölkerungsbasierte Studie zum Vergleich von Geburtskohorten aus Dänemark und Deutschland. Bremen. 2024.
  • Scholle OHF. Regionale Unterschiede bei ambulanten Antibiotikaverordnungen auf Kreis-Ebene: Einblicke in das SARA-Projekt. Bremen. 2023.
  • Scholle OHF. German Pharmacoepidemiological Research Database (GePaRD): Möglichkeiten und Grenzen. Berlin. 2019.

  • Posters at scientific meetings/conferences

  • Enners S, Schlotmann A, Schüssel K, Brückner G, Jobski K, Langner I, Thiede M, Scholle OHF. Regional variations in opioid prescribing in Germany on a district-level in 2023: A population-based study using claims data. Uppsala, Sweden. 2025.
  • Schäfer W, Scholle OHF, Viebrock J, Haug U. Use of testosterone-containing drugs in Germany: Time trends and potential off-label use. Münster. 2025.
  • Schäfer W, Scholle OHF, Viebrock J, Haug U. Use of testosterone-containing drugs in Germany: Time trends and potential off-label use. Uppsala, Sweden. 2025.
  • Scholle OHF, Jobski K, Viebrock J, Haug U. Use of transmucosal fentanyl in Germany (2005-2020): Insights from a large claims database. Uppsala, Sweden. 2025.
  • Scholle OHF, Thiyagarajan A, Koenen N, Haug U. Regional variations in the use of thyroid stimulating hormone measurements and levothyroxine in Germany: A small area analysis based on claims data. Berlin. 2024.
  • Scholle OHF, Buck C, Kollhorst B, Haug U. Explaining regional variations in outpatient antibiotic prescribing: A small area analysis including over 16 million persons in Germany. Halifax, Canada. 2023.
  • Wharton GT, Becker C, Bennett D, Burcu M, Bushnell G, Kaplan S, McMahon AW, Movva N, Raman SR, Scholle OHF, Suh M, Sun JW, Horton DB. Overview of global real-world data sources for pediatric pharmacoepidemiologic research. Halifax, Canada. 2023.
  • Bliddal M, Bachmann CJ, DosReis S, Odsbu I, Scholle OHF, Skurtveit S, Vivirito A, Wesselhoeft R, Scott S. So many countries, so many customs: A register-based analysis of conduct disorder prevalence and treatment patterns in four western countries. Copenhagen, Denmark. 2022.
  • Christ P, Rischke N, Dubrall D, Scholle OHF, Stausberg J, Haug U, Sachs B. WOLGA: Further development, optimization and application of an algorithm for the detection of serious adverse drug reactions based on claims data - First results of a sub-analysis focusing on clostridium difficile infections. Münster. 2022.
  • Scholle OHF, Rasmussen L, Reilev M, Viebrock J, Haug U. Outpatient antibiotic prescribing in early life: A population-based study comparing birth cohorts from Denmark and Germany. Copenhagen, Denmark. 2022.
  • Scholle OHF, Grill S, Haug U. Changes in early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. Online-Poster. 2020.
  • Scholle OHF, Grill S, Haug U. Changes in early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. online poster. 2020.
  • Scholle OHF, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. Online-Poster. 2020.
  • Scholle OHF, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. online poster. 2020.
  • Scholle OHF, Kollhorst B, Haug U. Are the risk minimization measures for diclofenac effective? A pre-post comparison based on German claims data. Philadelphia, USA. 2019.
  • Kölch M, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Scholle OHF. Predictors for pharmacological and psychotherapeutic treatment in children newly diagnosed with ADHD. Seattle, USA. 2018.
  • Scholle OHF, Banaschewski T, Jilani H, Riedel O, Pohlabeln H. Gebrauch von Nahrungsergänzungsmitteln bei Kindern mit medikamentös und nicht medikamentös behandelter ADHS. Bremen. 2018.
  • Scholle OHF, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Kölch M. Predictors for pharmacological and psychotherapeutic treatment in children newly diagnosed with ADHD. Prague, Czech Republic. 2018.
  • Castellsagué J, Calingaert B, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle OHF, Arana A, Bui C, Laguna C, Prados-Torres A, Roso-Llorach A, Perez-Gutthan S. Impact of risk-minimization measures on the use of cilostazol in Europe. Montreal, Canada. 2017.
  • Castellsagué J, Calingaert B, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle OHF, Varas-Lorenzo C, Arana A, Bui C, Prados-Torres A, Gonzalez-Rubio F, Roso-Llorach A, Citarella A, Garbe E, Blenk T, Perez-Gutthan S. Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany. Dublin, Ireland. 2016.

For further publications please follow this link:

  • Spotlight Poster Winner 2020 in the category of "Pediatrics"
    International Society for Pharmacoepidemiology (2020)
    Poster entitled "Changes in Early Life Exposure to Antibiotics: A Comparison of Birth Cohorts Based on German Claims Data"
  • ICPE Scholarship 2019
    International Society for Pharmacoepidemiology (2019)
    Teilnahme an der 35. International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Philadelphia, PA, USA

  • 2025/2026 Seminar in the core module “Epidemiological Study Designs and Statistical Methods”; Master’s program in Epidemiology; Johannes Gutenberg University Mainz
  • 2025/2026 Seminar in the elective module “Pharmacoepidemiology”; Master’s program in Health Sciences/Public Health; Technische Universität Dresden
  • 2025/2026 Practical course “Epidemiology” in the compulsory module “Epidemiology and Statistical Applications”; Department 11: Human and Health Sciences; University of Bremen
  • 2025 Course “Pharmacoepidemiology” and practical course in the module “Methodological Foundations of Epidemiology”; Master’s program in Medical Biometry/Biostatistics; Heidelberg University Hospital
  • 2024/2025 Seminar in the core module “Epidemiological Study Designs and Statistical Methods”; Master’s program in Epidemiology; Johannes Gutenberg University Mainz
  • 2024/2025 Practical course “Epidemiology” in the compulsory module “Epidemiology and Statistical Applications”; Department 11: Human and Health Sciences; University of Bremen
  • 2024 Seminar "Epidemiology I"; Bachelor's program Public Health/Health Science; Faculty 11: Human and Health Sciences; University of Bremen
  • 2023/24 Elective Module Pharmacoepidemiology in the Master's Program in Public Health/Health Sciences at TU Dresden
  • 2021/22 Elective Module Pharmacoepidemiology in the Master's Program in Public Health/Health Sciences at TU Dresden
  • May 2014 until April 2018 Subjects Pharmacy, Pharmaceutical Law & Pharmakology at the Pharmaakademie GmbH & Co. KG

The responsibility for the content of this page lies with Oliver H. F. Scholle.

Oliver H. F. Scholle

Contact

Phone:
+49 (0)421 218-56-878
E-mail:
scholle(at)leibniz-bips.de